Victor Araya, MD
Hepatology · Doylestown, PANPI 1285693069
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,145 of the $120,099 with a category attached, or 75.9%. Gilead accounts for 60.4% of it on its own, with 40 other manufacturers making up the rest.
Across 588 payments — averaging $204.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$73K
- Madrigal Pharmaceuticals$27K
- AbbVie$9K
- Shionogi Inc$4K
- Novo Nordisk$3K
- Intercept Pharmaceuticals, Inc.$885
- plus $4K from 35 others
Across 234 payments — averaging $3151.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$470K
- Intercept Pharma Europe Ltd.$110K
- Madrigal Pharmaceuticals$107K
- Boehringer Ingelheim International GmbH$42K
- Dova Pharmaceuticals$5K
- Novartis$2K
- plus $2K from 1 others
What the payments were for
- Consulting fees$6,6706%
- Speaking & faculty fees$91,14576%
- Travel & lodging$10,3359%
- Food & beverage$11,65810%
- Education$1590%
- Gifts$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hepatology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 13 | $231,758 |
| RezdiffraResmetirom | 16 | $108,535 |
| CreonLipase/Protease/Amylase | 30 | $30,507 |
| VemlidyTenofovir Alafenamide | 14 | $28,639 |
| LinzessLinaclotide | 31 | $25,392 |
| Ursodiol | 33 | $7,045 |
| Ondansetron Hcl | 30 | $5,909 |
| Dexlansoprazole DrDexlansoprazole | 21 | $5,023 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 32 | $5,015 |
| Pantoprazole Sodium | 167 | $1,592 |
| Famotidine | 129 | $1,484 |
| Mycophenolate Mofetil | 19 | $1,223 |
| Omeprazole | 144 | $1,058 |
| Esomeprazole Magnesium | 50 | $989 |
| Dicyclomine Hcl | 40 | $806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $885 | $231,75813 claims |
| Madrigal PharmaceuticalsRezdiffra | $26,682 | $108,53516 claims |
| AbbVieCreon, Linzess | $8,895 | $55,89861 claims |
| GileadVemlidy | $72,504 | $28,63914 claims |
| Braintree Laboratories, Inc.Sutab | $203 | $5,01532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other hepatology in Doylestown
- Shahid MalikAllentown$10K
- Yedidya SaimanPhiladelphia$7K
- Attiq Ur RehmanWilkes Barre$1K
- Cierra SmithPittsburgh$1K
- Caroline ConlonPhiladelphia$696
- Fei-Pi LinPittsburgh$267
- Alexandra GibasLancaster$209
- Carolyn HoganPhiladelphia$151
- Michael DunnPittsburgh$36
- Abdullah Al-OsaimiPhiladelphia$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.